Argenx SE’s Performance in Q1 2026
Baron Capital recently released its first-quarter investor letter for the Baron Health Care Fund, in which it highlighted the performance of Argenx SE (NASDAQ:ARGX). The fund, which saw a decline of 6.97% in the quarter, attributed part of its underperformance to its holdings in Argenx SE, a commercial-stage biopharma company.
Reasons Behind the Decline
Argenx’s stock faced challenges primarily due to two main factors. Firstly, the company’s operating expense guidance exceeded investor expectations, coupled with sales guidance indicating a seasonally weak Q1. Despite these short-term setbacks, Baron Capital maintains a positive long-term investment thesis in Argenx SE, emphasizing its leading development of Vyvgart, a prominent FcRn inhibitor for autoimmune conditions.
“Higher exposure to lagging life sciences tools & services stocks and weak stock selection in biotechnology contributed to the relative shortfall,” noted Baron Health Care Fund.
Another influential factor was the unexpected retirement of CEO Tim Van Hauwermeiren, who will transition to the role of non-executive chairman. His departure was seen as a potential risk, but the fund expressed confidence in the new CEO, Karen Massey, who was previously the company’s COO.
Market Response and Strategic Positioning
In response to the stock’s performance and to manage risk, Baron Capital reduced its position in Argenx SE. This decision came after the position size had increased due to multi-year share price appreciation. Notably, Argenx SE is not currently listed among the 40 most popular stocks among hedge funds, with 48 portfolios holding it at the end of the fourth quarter, down from 50 in the previous quarter.
Future Outlook
Despite these hurdles, Baron Capital and other investors remain optimistic about the long-term potential of Argenx SE, especially in light of its advancements in biotechnology and the broader positive outlook for health care driven by factors like an aging population and increased health care spending.
For those considering investment options, Baron Capital suggests exploring other sectors such as AI, which may offer greater upside potential with less risk.
Conclusion
While Argenx SE faced challenges in the first quarter of 2026, strategic adjustments and leadership changes are expected to position the company for future growth. Investors are advised to consider both the current challenges and the long-term potential of their investments in the biotechnology sector.
